Comprehensive insight regarding the cost and timing of peripherally acting mu-opioid receptor antagonist therapy in opioid-induced constipation.
Annette Hood, PharmD, BCACP, leads a discussion on the role of oncology pharmacists in supporting oncologists to determine the appropriate treatment plan for individuals with ovarian cancer.
Given the 3 available peripherally acting mu-opioid receptor antagonists for opioid-induced constipation, experts consider when to use a specific agent.
Considerations for the safety/efficacy profile of peripherally acting mu-opioid receptor antagonists, particularly given their administration route.
Key opinion leaders shift their attention to use of peripherally acting mu-opioid receptor antagonists in opioid-induced constipation.
A cohesive overview of the classes of agents used to treat patients with opioid-induced constipation.
A discussion on when to implement bevacizumab into the treatment plan and the rationale for using PARP inhibitors to treat individuals with ovarian cancer.
The panel reflects on the role of a pharmacist in the identification and management of opioid-induced constipation.
Expert physicians and pharmacists consider the frontline treatment approach, with special consideration of the roleo f frontline neoadjuvant chemotherapy in treating individuals with ovarian cancer.
Shared insight on the open dialogues that should take place between patients with opioid-induced constipation and care providers.
A discussion on the typical diagnostic work-up, including CT scan, tumor markers, colonoscopy, germline, and somatic testing.
Key opinion leaders provide an overview of ovarian cancer and consider the associated risk factors.